1. Home
  2. Directory
  3. California
  4. Yreka
  5. Obstetrics Gynecology
  6. NPI Profile
  7. Prescriptions 1215216643

MS. SARAH JANE NORRIS APRN, WHNP-BC
Prescription History 1215216643
Obstetrics & Gynecology in Yreka, CA

NPI Status: Active since August 16, 2011

Contact Information

FAIRCHILD MEDICAL CLINIC
475 BRUCE STREET
YREKA, CA
ZIP 96097
Phone: (415) 272-1174

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MS. SARAH JANE NORRIS APRN, WHNP-BC, an active Obstetrics & Gynecology specialist practicing in Yreka, CA. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 129 documented patient claims. Among these therapy options, the most frequently utilized medication is Estradiol, which accounts for 61 claims alone.

Medication Index

B
E
G
N
No matching medications currently found on file.

Betamethasone Dipropionate

Generic Formulation: Betamethasone DipropionateSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 13
30-Day Fills 19.5
Days Supply 439
CA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills34.6
Peer Average Days Supply917
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 59.4% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $826.46 across this reporting matrix range.

Provider Avg Cost Per Claim

$63.57

State Avg Cost Per Claim

$72.49

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat a variety of skin conditions (such as eczema, dermatitis, allergies, rash). Betamethasone reduces the swelling, itching, and redness that can occur in these types of conditions. This medication is a strong corticosteroid.

Estradiol

Generic Formulation: EstradiolSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 61
30-Day Fills 156.4
Days Supply 4,686
CA State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills89.7
Peer Average Days Supply2,679
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 84.8% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,100.79 across this reporting matrix range.

Provider Avg Cost Per Claim

$67.23

State Avg Cost Per Claim

$74.73

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Estring

Generic Formulation: EstradiolSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 14
30-Day Fills 41.6
Days Supply 1,248
CA State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills75.2
Peer Average Days Supply2,255
Conservative Utilization

This provider writes prescriptions for this formulation 44.0% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,790.98 across this reporting matrix range.

Provider Avg Cost Per Claim

$556.50

State Avg Cost Per Claim

$559.73

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Gemtesa

Generic Formulation: VibegronSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 29
30-Day Fills 29.0
Days Supply 870
CA State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills64.0
Peer Average Days Supply1,861
Conservative Utilization

This provider writes prescriptions for this formulation 35.6% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $14,690.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$506.58

State Avg Cost Per Claim

$653.96

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat overactive bladder. Overactive bladder is a problem with how your bladder stores urine that causes a sudden urge to urinate. The urge may be hard to control, and overactive bladder symptoms may include frequent urination, strong sudden urges to urinate, or involuntary loss of urine (incontinence). Vibegron works by relaxing a certain bladder muscle (detrusor), which helps the bladder hold more urine and lessens symptoms of overactive bladder.

Nystatin

Generic Formulation: NystatinSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 240
CA State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills23.3
Peer Average Days Supply496
Conservative Utilization

This provider writes prescriptions for this formulation 45.5% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $204.94 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.08

State Avg Cost Per Claim

$26.29

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Macrolide antifungal antibiotic complex produced by Streptomyces noursei, S. aureus, and other Streptomyces species. The biologically active components of the complex are nystatin A1, A2, and A3.

Therapeutic Applications

Nystatin is used to treat fungal skin infections. Nystatin is an antifungal that works by stopping the growth of fungus.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MS. SARAH JANE NORRIS APRN, WHNP-BC provides transparency into local medical care patterns within Yreka, CA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Obstetrics & Gynecology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.